{
}
Sanofi reported a business EPS of 2.86 euros for Q3 2024, reflecting a 12.2% increase on a reported basis and 17.6% at constant exchange rates, with sales exceeding 13.4 billion euros, up 12.3%. UBS has reiterated its Buy recommendation, maintaining a target price of 110 euros, citing strong sales and profitability gains expected for fiscal 2025. The company has also raised its 2024 outlook, anticipating business EPS growth at least in the low single digits.
The global pet healthcare market is projected to grow from $239.29 billion in 2023 to $255.96 billion in 2024, with a CAGR of 7.0%. Key drivers include an increasing pet population, advancements in veterinary care, and a focus on preventive health. By 2028, the market is expected to reach $353.66 billion, driven by trends such as pet humanization and economic prosperity.
Sanofi, Europe's largest pharmaceutical group, generates 70.6% of its net sales from pharmaceuticals, focusing on specialty and general medicine. Human vaccines account for 17.4%, while consumer health products make up 12%. Geographically, 43% of sales come from the U.S., with significant contributions from Europe and other regions.
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 110 euros. Analyst Jo Walton highlighted the company's strong growth distribution in his review of the quarterly report, indicating potential for revaluation.
The global diabetic retinopathy devices market, valued at USD 12.47 billion in 2022, is projected to grow at a robust CAGR of around 30% through 2030, driven by rising diabetes cases and an aging population. Non-proliferative diabetic retinopathy is expected to dominate, while North America will lead regionally, with significant contributions from the APAC region due to its large diabetic population. Key players include F. Hoffmann-La Roche, Novartis, and Regeneron, focusing on innovative treatments and technologies.
Sanofi's third-quarter earnings surged 25% in its vaccines division, driven by strong sales of Beyfortus, its RSV antibody for infants, which generated 645 million euros. Overall, the company reported total sales of $13.4 billion, exceeding Wall Street expectations and reflecting nearly 16% growth. The recent approval of a new manufacturing line aims to enhance Beyfortus supply amid high demand, ensuring access for all eligible infants in the U.S.
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 110 euros following the company's third-quarter results. Analyst Jo Walton noted that sales surpassed both his and consensus estimates, largely driven by strong vaccine sales.
UBS has maintained a "Buy" rating for Sanofi, setting a target price of 110 euros following the company's strong third-quarter results. Analyst Jo Walton noted that sales surpassed both his and consensus estimates, largely driven by vaccine sales.
Sanofi reported a profit increase driven by strong demand for seasonal vaccines and growth in its leading therapies, particularly Dupixent for skin and asthma conditions. In the third quarter, earnings per share, excluding certain items, reached €2.86 ($3.10), surpassing analysts' expectations, bolstered by early sales of influenza and respiratory syncytial virus vaccines.
Clayton Dubilier & Rice's pursuit of a €16 billion deal to acquire half of Sanofi's consumer arm, Opella, highlights the resurgence of the leveraged-finance market. Despite past setbacks with the Morrisons buyout, banks are eager to provide funding, driven by a need to generate fees as interest rates begin to stabilize.
Sanofi
Companies
| Symbol | SNY |
| Name | Sanofi |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | France |
| State | |
| City | Paris |
| Zipcode | 75008 |
| Website | http://www.sanofi.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Sanofi reports strong Q3 earnings prompting UBS to maintain buy rating
12:25 29.10.2024
global pet healthcare market projected to reach 353 billion by 2028
Elanco Animal Health Incorporated
Norbrook Laboratories Ltd.
PETCO Animal Supplies Inc.
Phibro Animal Health Corporation
Royal Canin
Merck & Co., Inc.
VCA Animal Hospitals Inc.
IDEXX Laboratories, Inc.
Perrigo Company plc
Chewy, Inc.
Colgate-Palmolive Company
Mars Inc.
Trupanion, Inc.
Nestlé S.A.
Zoetis Inc.
Sanofi
Boehringer Ingelheim International GmbH
Vetoquinol S.A.
Ceva Sante Animale SA
General Mills, Inc.
USA
IND
AUS
FRA
DEU
BRA
IDN
JPN
RUS
GBR
KOR
CHN
Sanofi SA
Mars Inc.
General Mills Inc.
Nestle SA
Merck & Co Inc.
Show more
03:01 29.10.2024
sanofi maintains strong market position with diverse product offerings and global reach
10:38 28.10.2024
ubs maintains buy rating for sanofi with target price of 110 euros
09:50 28.10.2024
diabetic retinopathy market poised for significant growth driven by rising diabetes cases
Indian Rupee
Pakistani Rupee
Chinese Yuan
United States Dollar
Regeneron Pharmaceuticals, Inc.
Sanofi
Coherus BioSciences, Inc.
Novartis AG
Bayer AG
Kodiak Sciences Inc.
HANLIM PHARM.CO.LTD
Intas Pharmaceuticals Ltd.
SUN Pharmaceutical Industries Ltd.
F. Hoffmann-La Roche Ltd.
PAK
CHN
IND
Bayer
Regeneron Pharmaceuticals
Sun Yat-Sen
Novartis
F. Hoffmann-La Roche
Show more
14:04 26.10.2024
Sanofi reports strong earnings driven by Beyfortus and vaccine sales
United States Dollar
Euro
Sanofi
Merck & Co., Inc.
AstraZeneca PLC
Pfizer Inc.
FRA
USA
Paul Hudson
Show more
17:50 25.10.2024
ubs maintains buy rating for sanofi with target price of 110 euros
13:25 25.10.2024
UBS maintains buy rating for Sanofi with target price of 110 euros
12:37 25.10.2024
sanofi reports profit increase driven by strong vaccine sales and dupixent growth
07:32 25.10.2024
banks eager to fund major buyout despite past setbacks
13:00 24.10.2024
Trending
Subcategory
Corporate News
Industry Trends
Global Trade Developments
Stock Market Updates
Cryptocurrency Trends
Startups & Entrepreneurship
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Supply Chain Management
Central Banks and Digital Currencies
CEO Changes
Workplace Trends
Blockchain Infrastructure Development
Banking Regulations
Central Bank Actions
Retail and Consumer Goods
Private Equity Deals
Global Financial Events
Government Economic Policies
Crypto Policies and Governance
Countries:
Companies:
Apple Inc.
Foxconn Technology Co., Ltd.
NVIDIA Corporation
Nasdaq 100 Jun 25
Boeing Co
Airbus SE
Amazon.com, Inc.
Oracle AI USD
AppLovin Corp.
Tesmec S.p.A.
DeepSeek R1 USD
LG Electronics Inc.
Tesla, Inc.
MARA Holdings, Inc.
Cleanspark Inc
Citigroup Inc.
Vodafone Idea Limited
JM Financial Limited
Fuse Science, Inc.
Arla Foods A.M.B.A.
Currencies:
People: